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Specimens from porcine pancreas and ileal mucosa were extracted in acid/ethanol, subjected to gel perme- 
ation chromatography, ion-exchange chromatography, enzymatic peptide degradation, reverse-phase 
HPLC, and analysed for glucagon-like and glicentin-like immunoreactivity by region-specific radioimmuno- 
assays. Results obtained with all methods were consistent with the hypothesis that glicentin is present in 
the pig pancreas in small amounts. 
Glicentin Proglucagon Gastrointestinal hormone Prohormone 
1. INTRODUCTION 
Glicentin is a 69-amino-acid protein found in pig 
intestinal mucosa. It contains the entire sequence 
of glucagon (residue 33-61) and is closely 
homologous to that of the 180-amino-acid 
glucagon precursor of hamster and man [1,2]. 
These preproglucagons contain 5 functional 
regions: a signal or pre-peptide, a 30-amino-acid 
NHz-terminal peptide related to GRPP (glicentin- 
related pancreatic peptide of pigs) [3], the 
glucagon sequence itself, and two carboxy- 
terminal glucagon-like peptides (GLP-1 and 
GLP-2). We here report the isolation of apparently 
intact glicentin from the pig pancreas, thus pro- 
viding evidence that this gut peptide is formed dur- 
ing the processing of pancreatic glucagon precur- 
sor as well. 
2. MATERIALS AND METHODS 
Porcine ileal mucosa and pancreatic tissues were 
extracted by an acid/ethanol method (method II in 
[4]). Tissues, obtained from anesthetized animals 
and frozen, immediately after excision, between 
blocks of dry ice, were homogenized in 
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acid/ethanol at -20°C and centrifuged. Diethyl 
ether, precooled to - 2O”C, was then added to the 
supernatant and the aqueous proteinaceous phase 
was isolated and redissolved in distilled water + 
8 M urea. Gel filtrations were performed on 50 x 
1000 mm columns (K SO/lOO) packed with 
Sephadex G-50 superfine (both from Pharmacia), 
equilibrated and eluted at 4°C with 0.5 M acetic 
acid at a flow rate of approx. 60 ml/h. Sample size 
never exceeded 2% of bed volume. Elution posi- 
tions are referred to by their coefficient of distribu- 
tion & = (V, - V,,)/Vi, where V, is the elution 
volume of the substance in question, V, is the ex- 
clusion volume of the gel, and Vi the available in- 
ner volume, determined as the difference between 
the elution volumes of 1251-labelled human 
albumin and 22NaC1 (both from The 
Radiochemical Centre, Amersham) added to all 
samples for internal calibration. In the enzymatic 
degradation experiment (see below) gel filtrations 
were performed on 16 x 1000 mm columns 
(K 16/100, Pharmacia) of Sephadex G-50 fine 
grade, equilibrated and eluted at 4°C with 0.125 M 
NH4HCO3, adjusted to pH 9.0 and supplemented 
with human serum albumin (1 g/l), NaCl (0.1 M) 
and thiomersal(0.6 mM), at a constant flow of ap- 
prox. 20 ml/h. Glicentin-containing fractions (as 
determined by radioimmunoassay, see below) were 
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freeze-dried, redissolved in 50 mM sodium 
phosphate buffer, pH 5.2, and subjected to ion- 
exchange chromatography. Ion-exchange ex- 
periments were performed on 9 x 150 mm columns 
of CM-Sepharose-CL-63 (Pharmacia), equili- 
brated and eluted at 4°C with the same buffer at 
pH 5.2 and a linear gradient reaching 0.5 M NaCl. 
Glicentin-containing fractions were pooled, freeze- 
dried, reconstituted in distilled water and applied 
to Sep-Pak C-18 cartridges (Water Associates, 
Milford, MA). The peptide was eluted at 4°C with 
a linear gradient of 0.1% trifluoroacetic acid 
(TFA) (Pierce, Rockford, IL) in water, reaching 
90% ethanol. Relevant fractions were collected, 
freeze-dried, redissolved in 0. f To TFA-2 M 
CH&OOH and subjected to HPLC. Reverse- 
phase HPLC was performed on 8 x 250 mm 
Nucleosil* 10 ,u C-18 columns, employing LKB 
(Bromma, Sweden) equipment (2150 HPLC pump, 
2152 HPLC controller, 2040-203 low-pressure mix- 
er valve). Elution phases were: (A) 0.1% TFA in 
double-distilled deionised water; (B) 0.05% TFA 
in 60% ethanol (Merck, Darmstadt, art.no.11727). 
The flow rate was 1.5 ml/min and eluted fractions, 
collected at l-min intervals, were blown dry under 
Nz and redissolved in assay buffer. Radioim- 
munoassays: (i) assays for the ~ucagon sequence 
6-15 were made with antiserum 4304, glucagon 
standards and ‘251-labelled glucagon as in [S]; (ii) 
assays for the glucagon sequence 19-29 were made 
with antiserum 4305, glucagon standards and 1251- 
labelled glucagon as in [5,6]; (iii) assays for the 
glicentin sequence 61-90 [7] were made with an- 
tiserum 4804 IS], glicentin standards and “‘I- 
labelled glicentin as in [9]; (iv) assays for the 
glicentin sequence 15-30 [7] were made with an- 
tiserum R64, glicentin standards and 1251-labelled 
glicentin [9]+ Incubation and separation pro- 
cedures have been described [lo]. Antiserum 4304 
binds labelled and unlabelled glucagon and glicen- 
tin with identical affinity [6], whereas antiserum 
4305 does not bind intact glicentin. Purified por- 
cine glicentin and glucagon standards, as well as 
monoiodinated tracers for both peptides, were 
kindly provided by Drs A.J. Moody and U.D. 
Larsen, The Novo Research Institute, Bagsvaerd, 
Denmark. Enzymic degradations of both intestinal 
glicentin and of pancreatic Kd 0.25 GLI peak were 
performed at 22°C for 30 min with bovine trypsin 
(TPCK-treated) (Worthington, Freehold, NJ) as in 
2 
[5], followed by inhibition by the addition of soya- 
bean trypsin inhibitor (T 9003, Sigma, St. Louis, 
MO). A further degradation was performed as 
above with carboxypeptidase B (phenylmethane- 
sulphonyl fluoride-treated) (Merck, art.no.2300). 
The incubations were terminated by the addition 
of aprotinin (5000 KIU at O’C) and the mixture 
was immediately applied to the column. 
3. RESULTS 
The binding sites of the antisera for the glucagon 
and the glicentin sequences are shown in fig. 1. 
Fig.2 (the whole right panel) is representative of 
the gel filtration profiles of the extracts of porcine 
pancreas (n = 6) as compared to the profiles of 
purified intestinal glicentin (from Novo); identical 
profiles were obtained with the peak fractions 
isolated from ileal mucosa. The assay for the N- 
terminal sequence of glicentin (residues 15-30) 
with antiserum R 64 shows a well defined peak at 
Kd 0.25 (range 0.24-0.26) (fig.2F); the assay 
against the midpart of glicentin (residues 39-48) 
with antiserum 4304 (fig.2B) showed recognition 
of immunoreactivity at Kd 0.25, which was also the 
case for antiserum 4804, directed against the C- 
terminal sequence of glicentin (residues 61-69) 
(fig.2H). Parallel results were obtained with the 
Fig.1. Schematic representation of the binding regions 
of the assay systems employed, as illustrated against the 
sequence of the glicentin molecule. A represents the 
entire ghcentin molecule; B represents the 33-69 
sequence of glicentin, and C the 33-61 sequence, which 
is identical with glucagon (stippled area). Note that the 
assay for the C-terminal glucagon sequence (with 
antiserum 4305) require unextended terminals of the 
glucagon sequence for binding. 
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Fig.2. Gel filtration profiles of extracts of porcine 
pancreas (B, D, F, H) and of purified glicentin (A, C, E, 
G) as measured by 6-15 immunoreactive (A, B) and 
19-29 immunoreactive (C, D) antisera to glucagon; 
15-30 immunoreactive (E, F) and 61-69 immunore- 
active (G, H) antisera to glicentin, and plotted against 
the coefficient of distribution, Kd. 
glicentin standards (fig.2A,C,E,G). Fractions cor- 
responding to the & 0.25 immunoreactivity from 
the gel filtration of several pancreas specimens 
were pooled, freeze-dried, and subjected to ion- 
exchange chromatography. Radioimmunoassays 
of the eluted fractions elicited a single im- 
munoreactive peak, at the same ionic strength, 
with both antiserum R64 and with antiserum 4804 
(fig.3). Fig.4 shows the results of limited tryptic 
digestion (10 pglml, 30 min, peptide/enzyme ratio 
approx. 1) followed by carboxypeptidase B treat- 
ment of both pancreatic Kd 0.25 immunoreactivity 
and of intestinal glicentin. Glicentin is no longer 
homogeneous: a new component is generated, ac- 
tive in the glucagon 19-29 assay (~tiserum 4305) 
at &I 0.85; in addition, a compound with ex- 
clusively glucagon 6- 15 immunoreactivity appears 
at & 0.78. Finally, glucagon 19-29 immunoreac- 
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Fig.3. Ion-exchange chromatographic elution profiles of purified glicentin (Ieft panel) and of pooled fractions from 
extracts of porc’ine pancreas (& 0.25, right panel), as measured by 15-30 immunoreactive (-) and 61-69 
immunoreactive (---) antisera to glicentin. The NaCl gradient, determined by measurement of conductivity, is also 
shown. 
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Fig.4. Gel filtration profiles of trypsin + carboxypeptidase B-digested Kd 0.25 GLI (left panel) and of intestinal glicentin 
(right panel) as measured by 6-15 immunoreactive (- ) and 19-29 immunoreactive (- - -) antisera to glucagon and 
plotted vs the coefficient of distribution, Kd. 
tivity appears at & 0.25. Furthermore, the pan- 
creatic & 0.25 immunoreactive peak was 
redissolved in 0.1% TFA-2 M CHKOOH and 
subjected to HPLC. As shown in fig.5, the peptide 
eluted at the expected retention time of purified 
glicentin, as was the case for intestinal mucosa & 
0.25 GLI peak when subjected to the same 
chromatographic procedure (fig.5). 
4. DISCUSSION 
Glicentin, first isolated and purified from pig in- 
testinal mucosa [1 1] and recognized as the major 
form of enteroglucagon in the pig [6,10,12], has 
the entire glucagon sequence at positions 33-61 
[5,13], and N-terminally, at positions l-30, and is 
composed of the glicentin-related pancreatic 
polypeptide (GRPP), a peptide which is secreted 
from the porcine pancreas synchronously and in 
equimolar amounts with glucagon [9]. Small 
amounts of a peptide with immunological and 
chromatographic characteristics of glicentin were 
found [9], and it was hypothesized that glicentin is 
4 
part of a common precursor molecule giving rise to 
both pancreatic and non-pancreatic glucagons 
[9- 11,131. Pancreatic glucagon precursors as from 
anglerfish pancreas [15-171 show the following 
organisation: a signal or prepeptide, the N- 
terminal GRPP, glucagon and one C-terminal 
glucagon-like peptide. Hamster pancreatic pre- 
proglucagon shows a similar structure, but for the 
presence of two C-terminal glucagon-like peptides 
(GLP-1 and GLP-2) [l], and is almost identical to 
the human pre-proglucagon 121. This study was 
undertaken to elucidate further the processing of 
proglucagon in pig pancreas. Glicentin found in 
pig ileal mucosa has been well characterized by 
immunological and chromatographic studies 
[5,6,9-133. We have here shown (fig.2) that the 
peptide isolated from pig pancreas has the same 
chromatographic haracteristics of glicentin stan- 
dards, thus pointing to its identity with the in- 
testinal mucosa peak I GLI 161. The enzymatic 
digestion of our & 0.25 pancreatic peak gave rise 
to a degradation fragment at Kd 0.78 bearing the 
immunodetermin~t for the glucagon sequence 
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Fig.5. Reverse-phase HPLC profile of purified glicentin 
(upper panel), pig pancreatic & 0.25 GLI (middle panel) 
and of pig ileal mucosa Kd 0.25 GLI (lower panel), as 
measured by the 6-15 immunoreactive antiserum to 
glucagon (- ). The UV detection at 226 nm of 
glicentin standard is indicated by an arrow. (The figure 
is representative of two identicai experiments for each 
peptide.) 
6- 15, common for any glu~agon-like immunoreac- 
tivity, and to a fragment at Kd 0.85 bearing the im- 
munodeterminant for the unextended glucagon se- 
quence 19-29, specific for pancreatic glucagon 
(fig.4); according to previous experience with the 
same column system 151, these elution positions 
correspond to the elution positions of fragments of 
glucagon corresponding to the 1-17 and 19-29 se- 
quences, respectively. Such was the case for both 
our pancreatic Kd 0.25 peptide and for the purified 
glicentin standard, suggesting that the pancreatic 
Kd 0.25 peptide contains sequences corresponding 
to the glucagon sequences l-17(-18) and 
18(fP)-29. Furthermore, the results of the 
radioimmunoassays of the fractions eluted from 
the ion-exchanger (fig.3) and the identity of the 
HPLC profile with that of purified glicentin 
(fig.5), are of considerable support in favour of the 
identity of the pancreatic Kd 0.25 peptide here 
described with glicentin. 
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